A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
Effectiveness and Safety of Consolidative Brentuximab Vedotin (BV) Treatment Administered to Hodgkin's Lymphoma (HL) Patients That Had Undergone Autologous Stem Cell Transplant (ASCT). Prospective, Multicenter, Observational Study
Takeda
70 participants
Mar 8, 2022
OBSERVATIONAL
Conditions
Summary
The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.
Eligibility
Inclusion Criteria1
- \. Adult participant (aged greater than or equal to \[\>=18\] years) that underwent or are candidates for ASCT and were enrolled in BV HL NDP receiving treatment according to the Summary of Product Characteristics for Adcetris and NDP.
Exclusion Criteria2
- Currently participates or plans to participate in any interventional clinical trial.
- Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Interventions
This is a non-interventional study.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05100056